Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695334 | 0.91 | MDM2 (0.35) | MDM2TP53ALDH1A1L3MBTL1TACR2 | |
| SCHEMBL3705051 | 0.90 | APAF1 (0.36) | MDM2TP53ALDH1A1L3MBTL1TACR2 | |
| SCHEMBL3708097 | 0.89 | TSHR (0.34) | MDM2TP53ALDH1A1L3MBTL1TACR2 | |
| SCHEMBL3701509 | 0.88 | KDM4E (0.40) | MDM2ALDH1A1TACR2EPHX2PPARG | |
| SCHEMBL3697424 | 0.87 | APAF1 (0.34) | MDM2TP53ALDH1A1L3MBTL1TACR2 | |
| SCHEMBL9101546 | 0.86 | C5AR1 (0.39) | ALDH1A1TACR2KDM4E | |
| SCHEMBL9104196 | 0.85 | MDM2 (0.35) | MDM2TP53ALDH1A1L3MBTL1TACR2 | |
| SCHEMBL3696385 | 0.85 | PTGS2 (0.37) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3700914 | 0.85 | TSHR (0.41) | TP53ALDH1A1USP2TSHR | |
| SCHEMBL3701950 | 0.85 | KCNJ1 (0.36) | MDM2TP53ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| EP-2460798-A2 | APAF-1 INHIBITOR COMPOUNDS | Laboratorios SALVAT, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | APAF1, API5, AIFM1 | MDM2 1367/4885TP53 336/4885ALDH1A1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.